The Efficacy and Safety of Umeclidinium/Vilanterol Inhalation Therapy in Individuals with Preserved Ratio Impaired Spirometry:A Multicenter, Randomized, Open-Label, Observer-Blind, Parallel-Design Clinical Trial

Start Date01 Jul 2026

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou Medical University

CTRI/2025/02/080495

/ RecruitingPhase 3

A prospective, randomized, double-blind, parallel, active-controlled, multicentre, phase III clinical trial to assess the efficacy and safety of Vilanterol, Umeclidinium and Fluticasone furoate inhalation as compared to Vilanterol and Fluticasone furoate inhalation in patients with uncontrolled asthma. - NIL

Start Date24 Feb 2025

Sponsor / Collaborator

Zydus Healthcare Ltd.

NCT07541378

/ SuspendedNot ApplicableIIT

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD: Randomised Crossover Study (COMPETE)

This study is designed to directly compare the effects of widely available long-acting bronchodilator therapies in patients with chronic obstructive pulmonary disease (COPD). The trial evaluates three fixed-dose combinations of a long-acting beta-2 agonist and a long-acting muscarinic antagonist (LABA/uLAMA)-umeclidinium/vilanterol (Anoro® Ellipta), indacaterol/glycopyrronium (Ultibro® Breezhaler), and tiotropium/olodaterol (Spiolto® Respimat)-against tiotropium (Spiriva®), a long-acting muscarinic antagonist (LAMA) used as monotherapy. The primary aim is to assess their impact on exercise capacity, with additional evaluation of pharmacoeconomic outcomes.
The study follows a prospective, randomized, open-label, four-period crossover design. Approximately 100 patients with stable COPD will be enrolled from the 2nd Department of Pulmonology and Tuberculosis, Medical University of Białystok, and the University Hospital Pulmonology Outpatient Clinic. Each treatment will last 28 days, separated by a 7-day wash-out period, so that every participant will receive each therapy.
Assessments will include standard clinical examinations, lung function testing (spirometry, body plethysmography, DLCO, multiple-breath washout), cardiopulmonary exercise testing (CPET) on a cycle ergometer, the 6-minute walk test, validated questionnaires (SGRQ, CAT, mMRC, BODE index), laboratory tests, and imaging. These procedures are part of routine COPD evaluation and will allow detailed monitoring of respiratory function, exercise tolerance, and quality of life.
The study aims to determine whether dual bronchodilation with LABA/uLAMA combinations provides superior improvements in exercise performance and overall efficiency compared to tiotropium alone. Results may help guide clinical decision-making and optimize cost-effectiveness in COPD management.

Start Date11 Mar 2024

Sponsor / Collaborator

Uniwersytet Medyczny w Bialymstoku

100 Clinical Results associated with Umeclidinium Bromide

100 Translational Medicine associated with Umeclidinium Bromide

100 Patents (Medical) associated with Umeclidinium Bromide

443

Literatures (Medical) associated with Umeclidinium Bromide

01 Jul 2026·Respiratory Investigation

Adherence to LAMA/LABA therapies in middle-aged patients with chronic obstructive pulmonary disease: A group-based trajectory analysis

Article

Author: Miyamoto, Atsushi ; Yoshida, Satomi ; Fukasawa, Toshiki ; Watanabe, Tetsuya ; Kawakami, Koji ; Hirai, Kaho ; Asai, Kazuhisa ; Liu, Hao ; Akaike, Takenori

BACKGROUND:

Longitudinal adherence patterns to LAMA/LABA therapy among middle-aged patients with COPD are not well understood. Because individuals aged 40-64 years typically self-manage medications with fewer age-related influences on adherence, this population allows clearer evaluation of temporal patterns. We therefore conducted a descriptive study among middle-aged patients to classify adherence trajectories and identify groups at risk of suboptimal adherence.

METHODS:

Using a Japanese claims database, we identified COPD patients aged 40-64 years who initiated glycopyrronium/indacaterol (GLY/IND), umeclidinium/vilanterol (UMEC/VI), or tiotropium/olodaterol (TIO/OLO). Group-based trajectory modeling was applied to the monthly proportion of days covered over 360 days to identify groups of patients with similar longitudinal adherence patterns.

RESULTS:

The analysis included 240 GLY/IND initiators, 365 UMEC/VI initiators, and 496 TIO/OLO initiators. For GLY/IND initiators, three adherence groups were identified: consistently high (31.7%), gradually declining (17.1%), and immediately declining (51.3%). UMEC/VI initiators demonstrated four groups: consistently high (26.6%), gradually declining (9.9%), rapidly declining (19.7%), and immediately declining (43.8%). TIO/OLO initiators also showed three groups: consistently high (35.5%), gradually declining (20.0%), and immediately declining (44.6%). Across all cohorts, higher adherence groups more frequently had a greater comorbidity burden and fewer previous moderate exacerbations, whereas suboptimal adherence groups tended to be younger, included more women, and initiated LAMA/LABA therapy in clinical settings.

CONCLUSIONS:

Middle-aged patients with COPD initiating LAMA/LABA therapy exhibited distinct adherence trajectories. Understanding these patterns may help inform more targeted approaches to support adherence and improve patient outcomes.

01 Jun 2026·Clinical Drug Investigation

Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis

Review

Author: Staatz, Christine E ; Baek, In-Hwan ; Han, Nayoung ; Kim, Younghwa ; Kim, Min-Soo ; Hwang, Eun Jung ; Koo, Hyunji ; Kim, Jiah

BACKGROUND:

Topical anticholinergic agents are non-invasive treatment options for primary axillary hyperhidrosis (PAH). Sofpironium bromide was recently approved by the US Food and Drug Administration (FDA). A comprehensive evaluation of the efficacy and safety of available topical anticholinergics may inform clinical practice.

OBJECTIVES:

To assess the efficacy and safety of topical anticholinergic therapies for PAH through systematic review and meta-analysis of randomized controlled trials (RCTs).

METHODS:

Five databases were searched on September 9, 2024. Primary outcomes included a ≥2-point improvement in the Hyperhidrosis Disease Severity Scale (HDSS) and ≥50% reduction in gravimetric sweat production (GSP). Secondary outcomes included subjective symptom improvement and objective sweat reduction. Safety outcomes included treatment-emergent adverse events (TEAEs), anticholinergic-related adverse events, and local application site reactions. The review protocol was registered in PROSPERO (CRD42024583376).

RESULTS:

Eight RCTs (n = 1921) that evaluated glycopyrronium, sofpironium bromide, and umeclidinium were included. Topical agents significantly outperformed placebos for HDSS ≥2-point improvement (risk ratio [RR]: 2.40; 95% confidence interval [CI]: 2.01-2.86) and GSP ≥50% reduction (RR: 1.43; 95% CI: 1.21-1.70). Sofpironium was the most effective HDSS treatment, whereas glycopyrronium showed highest efficacy against GSP. Topical agents were associated with increased risk of TEAEs (RR: 1.43; 95% CI: 1.14-1.79), with sofpironium associated with highest risk of dry mouth and glycopyrronium with highest risks for mydriasis and constipation.

CONCLUSIONS:

Topical anticholinergic agents are effective for PAH treatment, with distinct efficacy and safety profiles. Although the available evidence is limited by the small number of trials, short follow-up durations, and heterogeneity in outcome reporting, these findings support the role of topical anticholinergic therapy as an effective non-invasive option for PAH.

01 May 2026·ERJ Open Research

Cardiovascular events in patients with COPD after long-acting bronchodilator initiation

Article

Author: Kardos, Peter ; Newby, David E ; Sousa, Ana R ; Requena, Gema ; Slade, David ; Jonsson Funk, Michele ; Singh, Dave ; Roman-Rodriguez, Miguel ; Donald, Alison ; Compton, Chris

Background:

Real-world evidence concerning the cardiovascular (CV) risk of umeclidinium (UMEC) monotherapy or UMEC/vilanterol (VI) is scarce. This real-world study investigated CV risk in new users of UMEC or UMEC/VI versus new users of tiotropium (TIO) in patients with chronic obstructive pulmonary disease (COPD).

Methods:

This prospective, observational, multinational, cohort study enrolled patients ≥18 years with COPD who initiated UMEC, UMEC/VI or TIO between 2 February 2016 and 31 January 2023. Noninferiority (95% confidence interval upper bound <2.0) of UMEC and UMEC/VI to TIO was compared for the time-to-first event (hazard ratio (HR) over 24 months) of a composite CV end-point of myocardial infarction, stroke, heart failure or sudden cardiac death. Stabilised inverse probability of treatment weighting adjusted for differences in baseline covariate balance between groups. Incidence rates for the composite CV end-point were calculated.

Results:

In total, 6606 patients were enrolled; 6165 were included in the analysis. Both UMEC (n=1246) and UMEC/VI (n=2448) were noninferior to TIO (n=2471) for the risk of the composite CV end-point (adjusted HR (95% CI): UMEC versus TIO: 1.254 (0.830–1.896); UMEC/VI versus TIO: 1.352 (0.952–1.922)). Unadjusted composite CV incidence rates were low across cohorts (incidence rate (95% CI) per 100 person-years: UMEC: 1.157 (0.814–1.594); UMEC/VI: 1.287 (1.034–1.584); TIO: 0.924 (0.716–1.174)).

Conclusions:

Both UMEC and UMEC/VI were noninferior to TIO for composite CV risk, suggesting that physicians may consider escalating patients to dual bronchodilator therapy if COPD symptoms are not effectively managed with monotherapy.

News (Medical) associated with Umeclidinium Bromide

06 Jul 2026

·www.biospace.com

Vicore Pharma Appoints Rob Slack as Chief Scientific Officer

STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where he served as Vice President and Head of Respiratory Biology Stockholm, Sweden & Cambridge, Mass., July 6, 2026 - Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced the appointment of Rob Slack, PhD, FRSB, as Chief Scientific Officer. Dr. Slack succeeds Johan Raud, MD, PhD, who, after a long and distinguished career in drug discovery and a defining contribution to Vicore's science, will transition to Senior Advisor, supporting the company through key upcoming milestones. Dr. Slack brings more than 20 years of drug discovery leadership across biotech and large pharma. He joins Vicore from GSK, where he served as Vice President and Head of Respiratory Biology, and was previously acting Chief Scientific Officer at Galecto. Over his career he has helped deliver multiple approved respiratory medicines, including vilanterol (Breo®, Trelegy®) and umeclidinium (Anoro®, Trelegy®) for asthma and COPD, and led the discovery of the inhaled αvβ6 inhibitor GSK3008348 for IPF. A Fellow of the Royal Society of Biology with more than 60 publications, he holds a PhD from the University of Strathclyde. As Chief Scientific Officer, he will lead Vicore's research strategy and the continued development of the company's next-generation AT2 receptor agonist pipeline. "Rob is an outstanding scientific leader whose deep expertise in respiratory biology, drug discovery, and translational science will be instrumental as we advance buloxibutid and expand our pipeline. His appointment strengthens our early-stage pipeline efforts and research foundation at a pivotal moment for the company," said Ahmed Mousa, CEO of Vicore Pharma. "I also want to thank Johan for his extraordinary contributions as Chief Scientific Officer. Vicore's science is built on the foundation he helped create, and we are fortunate that he will continue to lend his insight and guidance as Senior Advisor." "The angiotensin II type 2 receptor is one of the most exciting and differentiated mechanisms I have come across in respiratory and fibrotic disease," said Rob Slack, PhD, FRSB, Chief Scientific Officer of Vicore Pharma. "Most current approaches in IPF focus on slowing disease progression. What attracted me to Vicore is the potential of AT2 receptor agonism to address the underlying biology that drives disease, creating the opportunity for true disease modification. Equally compelling is the breadth of the mechanism, with potential applications across a wide range of respiratory and fibrotic diseases beyond IPF. I am excited to lead the science behind buloxibutid and our next-generation pipeline as we work to bring transformative new therapies to patients." For further information, please contact: Megan Richards, VP of IR & Comms, +1 978 269 4372, megan.richards@vicorepharma.com Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements concerning Vicore Pharma, its leadership, its pipeline, and the development of buloxibutid. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks identified in the section entitled "Risk Factors" in Vicore Pharma's filings the U.S. Securities and Exchange Commission and discussed in Vicore Pharma's Swedish filings, its press releases, and the Registration Statements. Vicore Pharma cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Vicore Pharma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Vicore Pharma's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Attachments Vicore Pharma Appoints Rob Slack as Chief Scientific Officer SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire

Phase 2Fast TrackExecutive ChangeOrphan Drug

11 May 2026

·www.biospace.com

Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla. , May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-strength Trelegy ® Ellipta ®1 (200 mcg/62.5 mcg/25 mcg) product, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Based on the FDA's public records, 2 Transpire Bio believes that it was the first company to ANDA for the high-strength product with a Paragraph IV certification under the provisions of the Hatch-Waxman Act. Should Transpire Bio's ANDA be approved by the FDA, Transpire Bio believes it will be eligible for 180 days of market exclusivity. In the U.S., Trelegy ® Ellipta ® is indicated for the maintenance treatment of asthma in patients 18 years and older and the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). According to IQVIA, Trelegy ® Ellipta ® reported U.S. annual sales of $8 Billion in 2025. 3 "The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy ® Ellipta ® is another major milestone in advancing our development program and our complex generic franchise as a whole," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "Our highly experienced team in South Florida continues to meet and exceed each challenge put in front of them. With our first two ANDAs for generic Breo ® and Trelegy ® now confirmed as first-to-file, and this ANDA as our potentially third first-to-file, we move one step closer to providing patients suffering from asthma or COPD with an affordable option and improved access to this critical medication." "This milestone demonstrates Transpire Bio's strong capabilities in developing complex drug device combination products. We are extremely proud of the deep scientific and technical competence of our Transpire Bio team to constantly execute against our strategic plan," said Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio. In addition to its focused complex generic franchise, Transpire Bio is building a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), with three assets in development. Transpire Bio is also developing therapies for Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson's Disease Psychosis, and Glioblastoma. These products are being developed and manufactured in Transpire Bio's state-of-the-art manufacturing facilities located in South Florida, U.S. Trelegy ® Ellipta ® is a registered trademark of the GSK group of companies. FDA’s “Paragraph IV” patent certification list IQVIA NPA (US SMART Edition). Data on file. About Transpire Bio Inc. Transpire Bio Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio is innovating by applying its deep inhalation drug formulation and delivery expertise to respiratory and systemic diseases where currently available options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry-powder inhalers and soft-mist inhalers, and is progressing a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson's Disease Psychosis, and Glioblastoma. For more information, please visit . View original content to download multimedia: SOURCE Transpire Bio

25 Feb 2026

·www.drugs.com

Umeclidinium-Vilanterol Tied to Better Outcomes Than Other LAMA-LABA Inhalers in Symptomatic COPD

WEDNESDAY, Feb. 25, 2026 -- Umeclidinium-vilanterol is associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol in symptomatic patients with chronic obstructive pulmonary disease (COPD), according to a study published online Feb. 23 in JAMA Internal Medicine . Gerard T. Portela, Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues evaluated the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers. The analysis included claims data from 55,817 matched pairs (aged 40 years and older) newly treated with long-acting muscarinic antagonist–long-acting β 2 -agonist (LAMA-LABA) inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during a 183-day baseline period. The researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation versus glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95 percent confidence interval, 0.81 to 0.91; number needed to treat [NNT], 17). Umeclidinium-vilanterol also was associated with a lower risk compared with tiotropium-olodaterol (HR, 0.97; 95 percent confidence interval, 0.94 to 0.99; NNT, 100). Compared with glycopyrrolate-formoterol, tiotropium-olodaterol tended to be associated with a lower risk for a first moderate or severe COPD exacerbation (HR, 0.94; 95 percent confidence interval, 0.89 to 1.00). Across all three groups, the risks for first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were similar. "Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required)

Clinical Result

100 Deals associated with Umeclidinium Bromide

External Link

KEGG	Wiki	ATC	Drug Bank
D10181	Umeclidinium Bromide	R03BB07	DB09076

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Canada	GSK Plc	14 Mar 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis, Chronic	Phase 3	Germany	GSK Plc	06 Jul 2011
Hyperhidrosis Palmaris Et Plantaris	Phase 2	United States	GSK Plc	07 Mar 2016
Hyperhidrosis Palmaris Et Plantaris	Phase 2	Canada	GSK Plc	07 Mar 2016
Primary Axilary Hyperhidrosis	Phase 2	United States	GSK Plc	23 Nov 2015
Primary Axilary Hyperhidrosis	Phase 2	Canada	GSK Plc	23 Nov 2015
Asthma	Phase 2	United States	GSK Plc	03 Apr 2012
Asthma	Phase 2	Argentina	GSK Plc	03 Apr 2012
Asthma	Phase 2	Chile	GSK Plc	03 Apr 2012
Asthma	Phase 2	Russia	GSK Plc	03 Apr 2012
Asthma	Phase 2	Thailand	GSK Plc	03 Apr 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2025	Phase 3	Asthma \| Inflammation Maintenance blood eosinophils \| fractional exhaled nitric oxide	-	Fluticasone Furoate/Umeclidinium/Vilanterol	oywnlyyobt(rtqjygybsi) = oefwgpdupu dxwooxovts (wjpmwdwfet )	-	16 May 2025
				Fluticasone Furoate/Vilanterol	oywnlyyobt(rtqjygybsi) = eyhhvdyrcc dxwooxovts (wjpmwdwfet )
ATS2025	Phase 3	Pulmonary Disease, Chronic Obstructive	4,151	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	jbrcwvilug(mavrzgcwnu) = zaoluwfsls medxtsstil (kgbmkwyekk ) View more	Positive	16 May 2025
				Fluticasone Furoate/Vilanterol (FF/VI)	jbrcwvilug(mavrzgcwnu) = nqzsbwutxm medxtsstil (kgbmkwyekk ) View more
ATS2025	Phase 3	Asthma	-	FF/VI 100/25	qhqhwdigfj(rjosuplgmt) = jxstnkyxit qqekbbaoog (trgwcuyokh )	Positive	16 May 2025
				FF/VI 200/25	qhqhwdigfj(rjosuplgmt) = xpdpyuozxa qqekbbaoog (trgwcuyokh )
ELLITHE (ERS2024)	Not Applicable	Pulmonary Disease, Chronic Obstructive	617	Fluticasone furoate+Umeclidinium+Vilanterol	jlosqfwyud(xghyvothde) = hwughsesev erkkhhurbx (zkdeawhjhg ) View more	Positive	07 Sep 2024
ERS2023	Not Applicable	Pulmonary Disease, Chronic Obstructive	5,537	Multiple inhaler triple therapy (MITT)	wgdrqwecii(rrstpqokoi) = awqcflmife zagqwzszwt (rzehrxhzsc )	Positive	09 Sep 2023
NCT03034915 (EMAX, Pubmed \| Adv Ther)	Phase 4	Pulmonary Disease, Chronic Obstructive	2,696	Umeclidinium/vilanterol	abiyhukpue(sljhquajay) = lofnsxxzbf zrfafyfjip (bpmbhsuscj )	-	04 Aug 2021
				Umeclidinium	abiyhukpue(sljhquajay) = ionyxibbkl zrfafyfjip (bpmbhsuscj )
NCT02164513 (IMPACT, Pubmed \| Am J Respir Crit Care Med)	Phase 3	Pulmonary Disease, Chronic Obstructive	-	Fluticasone Furoate/Umeclidinium/Vilanterol 100/62.5/25µg	sgkhksgaor(tarqgrgnup): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387	Positive	15 Jun 2020
				Fluticasone Furoate/Vilanterol 100/25µg
NCT03012061 (GSK study ID: 205832, Pubmed \| Respir Res)	Phase 2	Asthma	421	UMEC 31.25 mcg	puauytmxmt(ptnwywsvso) = icyuyhpicj wyyyqjxwfm (gwbwgqoczv ) View more	Positive	12 Jun 2020
				UMEC 62.5 mcg	puauytmxmt(ptnwywsvso) = koaowhgjko wyyyqjxwfm (gwbwgqoczv ) View more
NCT02184611 (Pubmed) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive	306	Umeclidinium	ydhpsstvht(gufbdiperq): difference = 154 (95% CI, 113 - 194), P-Value = <0.001 View more	Positive	17 Apr 2020
				Placebo
NCT03034915 (EMAX, CTgov)	Phase 4	Pulmonary Disease, Chronic Obstructive	2,696	Placebo+UMEC/VI (UMEC/VI 62.5/25 mcg+ Placebo)	pibqjrcqnh(kbajmozyqs) = oinntvwtcl mxlvxomrre (llwubrapya, 0.0081) View more	-	15 Jul 2019
				Placebo+UMEC (UMEC 62.5 mcg + Placebo)	pibqjrcqnh(kbajmozyqs) = xemvzvjrpt mxlvxomrre (llwubrapya, 0.0085) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis